Valeant Pharmaceuticals Takes Another Hit as Takeda Deal Falls Through

Posted by Nick Buenaventura on Dec 1, 2016 10:18:10 AM

Controversial Valeant Pharmaceuticals (NYSE: VRX) in the news again as the deal to sell their division of Salix to the Japenese company, Takeda (TYO: 4502), broke down. The disagreement to sell the gastrointestinal-drugs division of Valeant caused further turmoil in their bonds as they dropped over 2 cents following the announcement. The volatility is nothing new to the pharmaceutical company as just earlier this month they experienced a significant drop in prices when they severed ties with Philidor Rx Services, LLC


The peaks and valleys of Valeant's bonds are captured by AdvantageData's charting tool.

Follow the developments in the pharmaceutical industry in real-time by requesting a free trial of AdvantageData today.


Topics: Valeant, Takeda, Salix, Philidor, Pharmaceuticals

From the leader in fixed income pricing and data comes market analytics and information you need now.

AdvantageData is your fixed income solution for pricing, analytics, reports, and insight on approximately:

  • 390,000+ U.S. and international corporate bonds
  • Over 5,200 CDS reference entities
  • Over 12,600 syndicated loans
  • 1,500 ETFs
  • Over 100 equity markets worldwide
  • One platform 12 asset classes from debt to CDS to loans to mid-market
  • Used by top buy and sell-side firms worldwide
Why aren't you using AdvantageData?

Subscribe to Email Updates

Recent Posts